Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03ZXZ
|
|||
| Former ID |
DND000002
|
|||
| Drug Name |
XL-228
|
|||
| Synonyms |
XL-228; 898280-07-4; XL228; UNII-33M2XSK003; 33M2XSK003; 4-N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-N-[(3-propan-2-yl-1,2-oxazol-5-yl)methyl]pyrimidine-2,4-diamine; SCHEMBL11342904; CHEMBL3545085; AOB5553; EX-A1596; BCP08143; XL 228; ZINC203005669; AKOS030526975; CS-1648; NCGC00378978-05; SC-95574; AS-16897; HY-15749; AC-30228; 2,4-Pyrimidinediamine, N(sup 4)-(5-cyclopropyl-1H-pyrazol-3-yl)-N(sup 2)-((3-(1-methylethyl)-5-isoxazolyl)methyl)-6-(4-methyl-1-piperazinyl)-; KB-303240
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Phase 1 | [1] | |
| Company |
Exelixis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H31N9O
|
|||
| Canonical SMILES |
CC(C)C1=NOC(=C1)CNC2=NC(=CC(=N2)N3CCN(CC3)C)NC4=NNC(=C4)C5CC5
|
|||
| InChI |
1S/C22H31N9O/c1-14(2)17-10-16(32-29-17)13-23-22-25-19(24-20-11-18(27-28-20)15-4-5-15)12-21(26-22)31-8-6-30(3)7-9-31/h10-12,14-15H,4-9,13H2,1-3H3,(H3,23,24,25,26,27,28)
|
|||
| InChIKey |
ALKJNCZNEOTEMP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 898280-07-4
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00526838) Study of XL228 Administered Intravenously to Subjects With Advanced Malignancies. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.